408 related articles for article (PubMed ID: 33353234)
21. Transcription factor B-cell-specific activator protein (BSAP) is differentially expressed in B cells and in subsets of B-cell lymphomas.
Krenacs L; Himmelmann AW; Quintanilla-Martinez L; Fest T; Riva A; Wellmann A; Bagdi E; Kehrl JH; Jaffe ES; Raffeld M
Blood; 1998 Aug; 92(4):1308-16. PubMed ID: 9694719
[TBL] [Abstract][Full Text] [Related]
22. Myeloid cell nuclear differentiation antigen is expressed in a subset of marginal zone lymphomas and is useful in the differential diagnosis with follicular lymphoma.
Metcalf RA; Monabati A; Vyas M; Roncador G; Gualco G; Bacchi CE; Younes SF; Natkunam Y; Freud AG
Hum Pathol; 2014 Aug; 45(8):1730-6. PubMed ID: 24925224
[TBL] [Abstract][Full Text] [Related]
23. Safety and tolerability of conditioning chemotherapy followed by CD19-targeted CAR T cells for relapsed/refractory CLL.
Geyer MB; Rivière I; Sénéchal B; Wang X; Wang Y; Purdon TJ; Hsu M; Devlin SM; Palomba ML; Halton E; Bernal Y; van Leeuwen DG; Sadelain M; Park JH; Brentjens RJ
JCI Insight; 2019 Apr; 5(9):. PubMed ID: 30938714
[TBL] [Abstract][Full Text] [Related]
24. Distribution and ZAP-70 expression of WHO lymphoma categories in Shanxi, China: a review of 447 cases using a tissue microarray technique.
Wang J; Young L; Win W; Taylor CR
Appl Immunohistochem Mol Morphol; 2005 Dec; 13(4):323-32. PubMed ID: 16280661
[TBL] [Abstract][Full Text] [Related]
25. Immunopathology of non-Hodgkin lymphomas.
Huber H; Gattringer C; Knapp W; Stein H
Klin Wochenschr; 1984 Nov; 62(21):1001-10. PubMed ID: 6392723
[TBL] [Abstract][Full Text] [Related]
26. Review: Current clinical applications of chimeric antigen receptor (CAR) modified T cells.
Geyer MB; Brentjens RJ
Cytotherapy; 2016 Nov; 18(11):1393-1409. PubMed ID: 27592405
[TBL] [Abstract][Full Text] [Related]
27. Diffuse large B-cell lymphoma (DLBCL) is infiltrated with activated CD8
Greenbaum AM; Fromm JR; Gopal AK; Houghton AM
Blood Res; 2022 Jun; 57(2):117-128. PubMed ID: 35551108
[TBL] [Abstract][Full Text] [Related]
28. Comparison of Myocyte Enhancer Factor 2B Versus Other Germinal Center-associated Antigens in the Differential Diagnosis of B-Cell Non-Hodgkin Lymphomas.
Moore EM; Swerdlow SH; Gibson SE
Am J Surg Pathol; 2018 Mar; 42(3):342-350. PubMed ID: 29309299
[TBL] [Abstract][Full Text] [Related]
29. Learning from the failures of drug discovery in B-cell non-Hodgkin lymphomas and perspectives for the future: chronic lymphocytic leukemia and diffuse large B-cell lymphoma as two ends of a spectrum in drug development.
Kubuschok B; Trepel M
Expert Opin Drug Discov; 2017 Jul; 12(7):733-745. PubMed ID: 28494631
[TBL] [Abstract][Full Text] [Related]
30. Genetically Determined Height and Risk of Non-hodgkin Lymphoma.
Moore A; Kane E; Wang Z; Panagiotou OA; Teras LR; Monnereau A; Wong Doo N; Machiela MJ; Skibola CF; Slager SL; Salles G; Camp NJ; Bracci PM; Nieters A; Vermeulen RCH; Vijai J; Smedby KE; Zhang Y; Vajdic CM; Cozen W; Spinelli JJ; Hjalgrim H; Giles GG; Link BK; Clavel J; Arslan AA; Purdue MP; Tinker LF; Albanes D; Ferri GM; Habermann TM; Adami HO; Becker N; Benavente Y; Bisanzi S; Boffetta P; Brennan P; Brooks-Wilson AR; Canzian F; Conde L; Cox DG; Curtin K; Foretova L; Gapstur SM; Ghesquières H; Glenn M; Glimelius B; Jackson RD; Lan Q; Liebow M; Maynadie M; McKay J; Melbye M; Miligi L; Milne RL; Molina TJ; Morton LM; North KE; Offit K; Padoan M; Patel AV; Piro S; Ravichandran V; Riboli E; de Sanjose S; Severson RK; Southey MC; Staines A; Stewart C; Travis RC; Weiderpass E; Weinstein S; Zheng T; Chanock SJ; Chatterjee N; Rothman N; Birmann BM; Cerhan JR; Berndt SI
Front Oncol; 2019; 9():1539. PubMed ID: 32064237
[TBL] [Abstract][Full Text] [Related]
31. T-cell redirecting therapies for B-cell non-Hodgkin lymphoma: recent progress and future directions.
Russler-Germain DA; Ghobadi A
Front Oncol; 2023; 13():1168622. PubMed ID: 37465110
[TBL] [Abstract][Full Text] [Related]
32. Cancer immune therapy for lymphoid malignancies: recent advances.
Klausen U; Jørgensen NGD; Grauslund JH; Holmström MO; Andersen MH
Semin Immunopathol; 2019 Jan; 41(1):111-124. PubMed ID: 30006739
[TBL] [Abstract][Full Text] [Related]
33. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.
Palanca-Wessels MC; Czuczman M; Salles G; Assouline S; Sehn LH; Flinn I; Patel MR; Sangha R; Hagenbeek A; Advani R; Tilly H; Casasnovas O; Press OW; Yalamanchili S; Kahn R; Dere RC; Lu D; Jones S; Jones C; Chu YW; Morschhauser F
Lancet Oncol; 2015 Jun; 16(6):704-15. PubMed ID: 25925619
[TBL] [Abstract][Full Text] [Related]
34. MRD Detection in B-Cell Non-Hodgkin Lymphomas Using Ig Gene Rearrangements and Chromosomal Translocations as Targets for Real-Time Quantitative PCR.
Pott C; Brüggemann M; Ritgen M; van der Velden VHJ; van Dongen JJM; Kneba M
Methods Mol Biol; 2019; 1956():199-228. PubMed ID: 30779036
[TBL] [Abstract][Full Text] [Related]
35. Non-Hodgkin lymphoma subtype distribution, geodemographic patterns, and survival in the US: A longitudinal analysis of the National Cancer Data Base from 1998 to 2011.
Al-Hamadani M; Habermann TM; Cerhan JR; Macon WR; Maurer MJ; Go RS
Am J Hematol; 2015 Sep; 90(9):790-5. PubMed ID: 26096944
[TBL] [Abstract][Full Text] [Related]
36. Current Immunotherapy Approaches in Non-Hodgkin Lymphomas.
Pytlik R; Polgarova K; Karolova J; Klener P
Vaccines (Basel); 2020 Nov; 8(4):. PubMed ID: 33260966
[TBL] [Abstract][Full Text] [Related]
37. Tracking the Genetic Susceptibility Background of B-Cell Non-Hodgkin's Lymphomas from Genome-Wide Association Studies.
Hernández-Verdin I; Labreche K; Benazra M; Mokhtari K; Hoang-Xuan K; Alentorn A
Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33374413
[TBL] [Abstract][Full Text] [Related]
38. Lenalidomide enhances antitumor functions of chimeric antigen receptor modified T cells.
Otáhal P; Průková D; Král V; Fabry M; Vočková P; Latečková L; Trněný M; Klener P
Oncoimmunology; 2016 Apr; 5(4):e1115940. PubMed ID: 27141398
[TBL] [Abstract][Full Text] [Related]
39. Chimeric Antigen Receptor-T-Cell Therapy for B-Cell Hematological Malignancies: An Update of the Pivotal Clinical Trial Data.
Roex G; Feys T; Beguin Y; Kerre T; Poiré X; Lewalle P; Vandenberghe P; Bron D; Anguille S
Pharmaceutics; 2020 Feb; 12(2):. PubMed ID: 32102267
[TBL] [Abstract][Full Text] [Related]
40. Genome-wide homozygosity and risk of four non-Hodgkin lymphoma subtypes.
Moore A; Machiela MJ; Machado M; Wang SS; Kane E; Slager SL; Zhou W; Carrington M; Lan Q; Milne RL; Birmann BM; Adami HO; Albanes D; Arslan AA; Becker N; Benavente Y; Bisanzi S; Boffetta P; Bracci PM; Brennan P; Brooks-Wilson AR; Canzian F; Caporaso N; Clavel J; Cocco P; Conde L; Cox DG; Cozen W; Curtin K; De Vivo I; de Sanjose S; Foretova L; Gapstur SM; Ghesquières H; Giles GG; Glenn M; Glimelius B; Gao C; Habermann TM; Hjalgrim H; Jackson RD; Liebow M; Link BK; Maynadie M; McKay J; Melbye M; Miligi L; Molina TJ; Monnereau A; Nieters A; North KE; Offit K; Patel AV; Piro S; Ravichandran V; Riboli E; Salles G; Severson RK; Skibola CF; Smedby KE; Southey MC; Spinelli JJ; Staines A; Stewart C; Teras LR; Tinker LF; Travis RC; Vajdic CM; Vermeulen RCH; Vijai J; Weiderpass E; Weinstein S; Doo NW; Zhang Y; Zheng T; Chanock SJ; Rothman N; Cerhan JR; Dean M; Camp NJ; Yeager M; Berndt SI
J Transl Genet Genom; 2021; 5():200-217. PubMed ID: 34622145
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
